WO2015085075A1 - Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance - Google Patents
Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance Download PDFInfo
- Publication number
- WO2015085075A1 WO2015085075A1 PCT/US2014/068579 US2014068579W WO2015085075A1 WO 2015085075 A1 WO2015085075 A1 WO 2015085075A1 US 2014068579 W US2014068579 W US 2014068579W WO 2015085075 A1 WO2015085075 A1 WO 2015085075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- myd88
- subject
- igm
- biological sample
- mutation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/547—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame spiro-condensed or forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Definitions
- WM Waldenstrom' s macro globulinemia
- LPL lymphoplasmacytic lymphoma
- Genetic factors play an important role in the pathogenesis of WM, with 25% of patients demonstrating a family history.
- IgM monoclonal gammopathy of unknown significance IgM MGUS
- delta C T values of a somatic mutation in the myeloid differentiation primary response (MYD88) gene determined using quantitative allele- specific polymerase chain reaction is lower in Waldenstrom's macroglobulinemia patients than in IgM monoclonal gammopathy of unknown significance patients.
- the present application provides convenient methods to discriminate WM from IgM MGUS based on the delta C T value for the mutant MYD88 gene.
- the present invention involves a method to distinguish Waldenstrom' s Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance in a subject.
- the method comprises obtaining a biological sample from a subject in need thereof, performing an allele- specific polymerase chain reaction assay to determine in the biological sample a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2, and providing a report indicating whether delta CT value of the biological sample is less than a reference value, wherein the subject is more likely to have Waldenstrom's Macroglobulinemia than IgM monoclonal gammopathy of undetermined significance if the delta CT value is less than the reference value.
- the biological sample is a sample of bone marrow, lymph node, spleen or blood.
- the mutation results in a single nucleotide change from T to C in the myeloid differentiation primary response 88 (MYD88) gene.
- the mutation results in an amino acid change from leucine to proline at position 265 in the myeloid differentiation primary response 88 protein.
- the allele specific polymerase chain reaction assay is performed using an allele specific primer, wherein the allele specific primer hybridizes at or near its 3' end to the mutation at position 38182641 in chromosome 3p22.2.
- the allele specific primer is SEQ ID NO: 1.
- a method to treat Waldenstrom's Macroglobulinemia in a subject comprises performing an allele-specific polymerase chain reaction assay to determine a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2 in a biological sample obtained from a subject in need thereof, and administering to the subject a therapeutic agent in an amount effective to treat Waldenstrom' s Macroglobulinemia if delta CT value of the biological sample is less than a reference value.
- the biological sample is a sample of bone marrow, lymph node, spleen or blood.
- the mutation results in a single nucleotide change from T to C in the myeloid differentiation primary response 88 (MYD88) gene.
- the mutation results in an amino acid change from leucine to proline at position 265 in the myeloid differentiation primary response 88 protein.
- the therapeutic agent is a MYD88 inhibitor, an interleukin receptor associate kinase 1/4 (IRAK- 1/4) inhibitor, a phosphoinositide 3-kinase (PI3K) inhibitor and/or a Bruton's tyrosine kinase (BTK) inhibitor.
- the MYD88 inhibitor is a peptidomimetic compound ST2825.
- the IRAK- 1/4 inhibitor is N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)-benzimidazole.
- the BTK inhibitor is Ibrutinib (PCI-32765).
- a method to distinguish Waldenstrom' s Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance comprises selecting a subject on the basis that the subject presents one or more of clinical features of WM and/or IgM MGUS, obtaining a biological sample from the subject, performing an allele- specific polymerase chain reaction assay to determine in the biological sample a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2, and providing a report indicating whether delta CT value of the biological sample is less than a reference value, wherein the subject is more likely to have Waldenstrom's Macroglobulinemia than IgM monoclonal gammopathy of undetermined significance if the delta CT value is less than the reference value.
- the biological sample is a sample of bone marrow, lymph node, spleen or blood.
- the mutation results in a single nucleotide change from T to C in the myeloid differentiation primary response 88 (MYD88) gene.
- the mutation results in an amino acid change from leucine to proline at position 265 in the myeloid differentiation primary response 88 protein.
- the allele specific polymerase chain reaction assay is performed using an allele specific primer, wherein the allele specific primer hybridizes at or near its 3' end to the mutation at position 38182641 in chromosome 3p22.2.
- the allele specific primer is SEQ ID NO: 1.
- a method to distinguish Waldenstrom' s Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance comprises performing an assay to determine if the subject has an abnormal level of immunoglobulin M (IgM) in a biological sample obtained from a subject, and performing an allele- specific polymerase chain reaction assay to determine a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2 in a biological sample obtained from a subject, wherein the subject is more likely to have Waldenstrom's Macroglobulinemia than IgM monoclonal gammopathy of undetermined significance if the subject has an abnormal level of IgM and delta CT value of the biological sample is less than a reference value.
- IgM immunoglobulin M
- the biological sample used to determine if the subject has an abnormal level of IgM is a sample of blood, urine, bone marrow, lymph node, or spleen.
- the biological sample used to determine the level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2 is a sample of blood, bone marrow, lymph node, or spleen.
- the mutation results in a single nucleotide change from T to C in the myeloid differentiation primary response 88 (MYD88) gene.
- the mutation results in an amino acid change from leucine to proline at position 265 in the myeloid differentiation primary response 88 protein.
- the allele specific polymerase chain reaction assay is performed using an allele specific primer, wherein the allele specific primer hybridizes at or near its 3' end to the mutation at position 38182641 in chromosome 3p22.2.
- the allele specific primer is SEQ ID NO: 1.
- FIG. 1 shows real-time AS-PCR results for PB MYD88 L265P in patients with WM, IgM MGUS, other B-cell disorders, and healthy donors.
- the light grey bar represents the distance between the highest positive, and lowest negative ACt values.
- Fig. 2 shows the real-time AS-PCR results for paired BM and PB MYD88 L265P in patients with WM and IgM MGUS.
- Fig. 2B shows the correlation of real-time AS-PCR results for paired BM and PB MYD88 L265P ACt in untreated patients with IgM MGUS, smoldering and symptomatic WM.
- MYD88 myeloid differentiation primary response
- WM Waldenstrom's macroglobulinemia
- the present invention is based on the surprising discovery that delta C T value for the mutant MYD88 L265P identified using quantitative allele-specific polymerase chain reaction (AS-PCR) assay is lower in WM patients than in IgM MGUS patients.
- AS-PCR quantitative allele-specific polymerase chain reaction
- the present invention provides a method to distinguish
- WM from IgM MGUS in a subject comprising obtaining a biological sample from a subject in need thereof, performing an allele-specific polymerase chain reaction assay to determine in the biological sample a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2, providing a report indicating whether delta CT value of the biological sample is less than a reference value, wherein the subject is more likely to have Waldenstrom's Macroglobulinemia than IgM monoclonal gammopathy of undetermined significance if the delta C T value is less than a reference value.
- WM is a B-cell neoplasm categorized as an IgM secreting lymphoplasmacytic lymphoma (LPL) by the WHO classification system.
- LPL lymphoplasmacytic lymphoma
- the disease is primarily characterized by bone marrow (BM) infiltration with lymphoplasmacytic cells (LPC), though up to 20% of patients can exhibit extramedullary disease.
- Circulating WM cells identified by flow cytometry or clonotypic IgM V/D/J rearrangements are present in WM patients, and parallel disease burden.
- the diagnosis of WM is contingent on demonstrating a LPC infiltrate, most typically by BM biopsy which can produce patient discomfort, result in unforeseen complications, represent a significant burden of cost, as well as delay the diagnosis of WM.
- IgM Monoclonal gammopathy of undetermined significance is an asymptomatic premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. This condition is clinically significant because of the high likelihood that in some patients IgM MGUS will progress to lymphoma or Waldenstrom's
- the methods described herein may be used to determine whether a subject is more likely to have WM than IgM MGUS, based on the delta C T value for the mutant MYD88 L265P.
- a subject may be diagnosed as being "more likely” or “less likely” to have WM than IgM MGUS in light of the information provided by a method of the present invention.
- the methods described herein may be used in conjunction with other diagnostic tests, such as but not limited to, bone marrow biopsies and blood tests, to help confirm the diagnosis.
- the methods described herein are used to determine if the subject has WM.
- the methods described herein are used to rule out a diagnosis of IgM MGUS.
- the methods described herein may be used to determine whether a subject is more likely to have IgM MGUS than WM, based on the delta C T value for the mutant MYD88 L265P.
- the methods described herein are used to determine if the subject has IgM MGUS.
- the methods described herein are used to rule out a diagnosis of WM.
- mutation means any change or difference in the nucleic acid or protein sequence of MYD88 as compared to the wild type sequence that results in the activation of MYD88 which leads to the activation of NF- ⁇ . Mutations may be identified by comparing the sequence of a subject to that of a wildtype individual or to reference sequences found in the public databases. Mutations include, but are not limited to, nonsense mutations, missense mutations, frameshift mutations, rearrangement mutations, insertion mutations and deletion mutations.
- the mutation is a somatic mutation at position 38182641 in chromosome 3p22.2 which results in a single nucleotide change from T— >C in the myeloid differentiation primary response (MYD88) gene, and a predicted non-synonymous change at amino acid position 265 from leucine to proline (L265P).
- a transcript comprising a mutation means MYD88 nucleic acid that has a mutation at position 38182641 in chromosome 3p22.2. In normal (healthy) subjects the mutation is absent. Although it is believed that most of the transcription of the MYD88 gene occurs in the bone marrow, levels of the transcript and protein will be present in the circulation because of the normal turnover and presence of dead cells in the blood.
- the level of the transcript comprising a mutation at position 38182641 in chromosome 3p22.2 is determined by allele specific polymerase chain reaction (AS-PCR).
- AS-PCR allele specific polymerase chain reaction
- Quantitative AS-PCR for MYD88-L265P may be performed as described in Xu et al. (Blood. 2013 Mar 14;121(l l):2051-8) and in WO 2013/006443, the contents of each of which are incorporated herein by reference. Allele specific primers are used which hybridize at or near their 3' ends to a particular mutation in the MYD88 gene. If the mutation is not present, the 3'-terminal mismatched primer does not initiate replication, and an amplification product is not observed.
- the allele specific primer is SEQ ID NO: 1.
- the mutation is a somatic mutation at position 38182641 in chromosome 3p22.2 which results in a single nucleotide change from T— >C in the myeloid differentiation primary response (MYD88) gene, and a predicted non- synonymous change at amino acid position 265 from leucine to proline (L265P).
- Levels of the transcript comprising a mutation at position 38182641 in chromosome 3p22.2 in patient samples can be calculated based on the value of delta C T determined using AS-PCR.
- C T or threshold cycle refers to the PCR cycle number at which the reporter fluorescence crosses a threshold set by the user.
- delta C T also called “ACt” refers to the difference between the threshold cycle of the mutant and the wild type at the selected threshold. If the delta C T is less than a reference value, the subject is diagnosed as having WM.
- a reference value represents the delta C T cutoff value that can differentiate between subjects with WM and IgM MGUS, and may vary depending on the assay conditions, and the primers used.
- a reference value can be identified by determining the MYD88 L265P delta C T value in subjects known to have WM and the MYD88 L265P delta C T value in subjects known to have IgM MGUS. A reference value is then selected such that all subjects with WM have a delta C T value that is less than the selected reference value and all subjects with IgM MGUS have a delta C T value that is higher than the selected reference value.
- a reference value represents a delta C T value such that 50%, 60%, 70%, 80%, 85%, 90%, 95% or 99% of the subjects with WM have a delta C T value that is less than the selected reference value, while 50%, 60%, 70%, 80%, 85%, 90%, 95% or 99% of the subjects with IgM MGUS have a delta Ct value that is more than the selected reference value.
- the present invention covers any one of the above mentioned percentage values for WM and any one of the above mentioned percentage values for IgM MGUS.
- a reference value may represent a delta C T value such that 85% of the subjects with WM have a delta C T value that is less than the selected reference value, and 60% of the subjects with IgM MGUS have a delta Ct value that is more than the selected reference value.
- 90% of the subjects with WM have a delta C T value that is less than the selected reference value
- 90% of the subjects with IgM MGUS have a delta Ct value that is more than the selected reference value.
- 95% of the subjects with WM have a delta C T value that is less than the selected reference value
- 100% of the subjects with IgM MGUS have a delta Ct value that is more than the selected reference value.
- 100% of the subjects with WM have a delta C T value that is less than the selected reference value, and 80% of the subjects with IgM MGUS have a delta Ct value that is more than the selected reference value.
- the reference value is about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9, 9.5 or 10. In some embodiments, the reference value is 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9, 9.5 or 10. In some embodiments, the reference value is about 6.5. In some embodiments, the reference value is 6.5.
- a "subject in need thereof is a subject suspected of having WM or IgM MGUS.
- the subject presents one or more clinical features of WM and/or IgM MGUS.
- the one or more clinical features of WM include anemia, hyper- viscosity, neuropathy, coagulopathies, splenomegaly, hepatomegaly, adenopathy, an elevated serum IgM levels and the presence of an IgM monoclonal protein.
- the one or more clinical features of IgM MGUS include monoclonal paraprotein band lesser than 30 g/L ( ⁇ 3g/dL), plasma cells less than 10% on bone marrow examination, no evidence of bone lesions, anemia, hypercalcemia, or renal insufficiency related to the paraprotein, and no evidence of another B-cell proliferative disorder.
- a subject in need thereof presents two or more, three or more, four or more, five or more, six or more, or seven or more of the above described clinical features of WM and/or IgM MGUS.
- the subject is a mammal. In some embodiments, the subject is a human.
- Non-limiting examples of the biological sample include bone marrow, lymph node, spleen or blood.
- the biological sample is blood.
- Obtaining a biological sample from a subject means taking possession of a biological sample of the subject.
- the biological sample may be removed from the subject by a medical practitioner (e.g., a doctor, nurse, or a clinical laboratory practitioner), and then provided to the person determining the presence of the mutation.
- the biological sample may be provided to the person determining the mutation by the subject or by a medical practitioner (e.g., a doctor, nurse, or a clinical laboratory practitioner).
- the person determining the mutation obtains a biological sample from the subject by removing the sample from the subject.
- a report summarizing the results of the analysis i.e. delta C T of the mutation and any other information pertaining to the analysis could optionally be generated as part of the analysis (which may be interchangeably referred to herein as “providing” a report, “producing” a report, or “generating” a report).
- Examples of reports may include, but are not limited to, reports in paper (such as computer-generated printouts of test results) or equivalent formats and reports stored on computer readable medium (such as a CD, computer hard drive, or computer network server, etc.).
- Reports can be part of a database (such as a database of patient records, which may be a "secure database” that has security features that limit access to the report, such as to allow only the patient and the patient's medical practitioners to view the report, for example).
- a database such as a database of patient records, which may be a "secure database” that has security features that limit access to the report, such as to allow only the patient and the patient's medical practitioners to view the report, for example.
- reports can also be displayed on a computer screen (or the display of another electronic device or instrument).
- a report can further be transmitted, communicated or reported (these terms may be used herein interchangeably), such as to the individual who was tested, a medical practitioner (e.g., a doctor, nurse, clinical laboratory practitioner, genetic counselor, etc.), a healthcare organization, a clinical laboratory, and/or any other party intended to view or possess the report.
- the act of 'transmitting' or 'communicating' a report can be by any means known in the art, based on the form of the report, and includes both oral and non-oral transmission.
- "transmitting" or "communicating" a report can include delivering a report ("pushing") and/or retrieving ("pulling") a report.
- non-oral reports can be transmitted/communicated by such means as being physically transferred between parties (such as for reports in paper format), such as by being physically delivered from one party to another, or by being transmitted
- a method to distinguish Waldenstrom' s Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance comprising selecting a subject on the basis that the subject presents one or more clinical features of WM and/or IgM MGUS, obtaining a biological sample from the subject, performing an allele- specific polymerase chain reaction assay to determine in the biological sample a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2, and providing a report indicating whether delta CT value of the biological sample is less than a reference value, wherein the subject is more likely to have Waldenstrom's Macroglobulinemia than IgM monoclonal gammopathy of undetermined significance if the delta CT value is less than the reference value.
- selecting a subject means identifying a subject that presents one or more clinical features of WM and/or IgM MGUS for further diagnostic analysis.
- the one or more clinical features of WM include anemia, hyper- viscosity, neuropathy, coagulopathies, splenomegaly, hepatomegaly, adenopathy, and an IgM serum
- the one or more clinical features of IgM MGUS include monoclonal paraprotein band lesser than 30 g/L ( ⁇ 3g/dL), plasma cells less than 10% on bone marrow examination, no evidence of bone lesions, anemia, hypercalcemia, or renal insufficiency related to the paraprotein, and no evidence of another B-cell proliferative disorder.
- a subject presenting two or more, three or more, four or more, five or more, six or more, or seven or more of the above described clinical features of WM and/or IgM MGUS is selected.
- the subject is selected by a medical practitioner (e.g., a doctor, nurse, clinical laboratory practitioner, genetic counselor, etc.), a healthcare organization, or a clinical laboratory.
- a method to distinguish Waldenstrom' s Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance comprising performing an assay to determine if the subject has an abnormal level of immunoglobulin M (IgM) in a biological sample obtained from a subject, and performing an allele- specific polymerase chain reaction assay to determine a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2 in a biological sample obtained from a subject, wherein the subject is more likely to have Waldenstrom' s Macroglobulinemia than IgM monoclonal gammopathy of undetermined significance if the subject has an abnormal level of IgM and delta CT value of the biological sample is less than a reference value.
- IgM immunoglobulin M
- an abnormal level of IgM refers to a level that is higher than the level found in normal (healthy) subject. Typically, normal serum IgM levels in adults are in the range of 45 to 250 mg/dL.
- levels of serum IgM greater than 500 mg/dl, 1 g/dl, 1.5 g/dL, 2g/dl, 2.5g/dl, 3g/dl, or 3.5g/dL are considered to be abnormal, and indicate a diagnosis of WM, rather than IgM MGUS.
- levels of serum IgM greater than 2g/dL are considered to be abnormal.
- levels of serum IgM greater than 3g/dL are considered to be abnormal.
- Non-limiting examples of biological samples used to determine if the subject has an abnormal level of IgM include blood, urine, bone marrow, lymph node, or spleen.
- Non-limiting examples of biological samples used to determine the level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2 include blood, bone marrow, lymph node, or spleen.
- two distinct biological samples are obtained from the subject to perform the assays to determine if the subject has an abnormal level of IgM and to determine the level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2.
- a single biological sample is obtained from the subject and is used to determine both if the subject has an abnormal level of IgM and the level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2.
- the subject is diagnosed as being more likely to have WM than IgM MGUS if the subject has an abnormal level of IgM and delta C T value of the biological sample is less than a reference value.
- methods to treat Waldenstrom' s Macroglobulinemia in a subject comprise performing an allele- specific polymerase chain reaction assay to determine a level of a transcript comprising a mutation at position 38182641 in chromosome 3p22.2 in a biological sample obtained from a subject in need thereof, and administering to the subject a therapeutic agent in an amount effective to treat Waldenstrom' s Macroglobulinemia if delta C T value of the biological sample is less than a reference value.
- the therapeutic agent can be any agent known to be useful in the treatment of
- therapeutic agents include, but at not limited to, myeloid
- MYD88 differentiation primary response 88
- IRAK- 1/4 interleukin receptor associate kinase 1/4
- PI3K phosphoinositide 3 -kinase
- BTK Bruton's tyrosine kinase
- MYD88 inhibitors include the peptidomimetic compound ST2825 (WO 2006/06709).
- IRAK- 1/4 inhibitor is N-(2-Morpholinylethyl)-2-(3-nitrobenzoylamido)- benzimidazole.
- BTK inhibitors useful in the instant invention block MYD88 L265P and BTK signaling.
- a non-limiting example of a BTK inhibitor includes Ibrutinib (PCI-32765).
- Non-limiting examples of PI3K inhibitors are described in WO 2013/052699.
- the therapeutic agent is administered in an effective amount.
- An effective amount is a dose sufficient to provide a medically desirable result and can be determined by one of skill in the art using routine methods.
- an effective amount is an amount which results in any improvement in the condition being treated.
- an effective amount may depend on the extent of WM being treated and/or use of one or more additional therapeutic agents. However, one of skill in the art can determine appropriate doses and ranges of therapeutic agents to use, for example based on in vitro and/or in vivo testing and/or other knowledge of compound dosages.
- a maximum dose is used, that is, the highest safe dose according to sound medical judgment.
- an effective amount is that amount which slows the progression of the disease, halts the progression of the disease, or reverses the progression of the disease.
- An effective amount includes, but is not limited to, that amount necessary to slow, reduce, inhibit, ameliorate or reverse one or more symptoms associated with WM. In some embodiments, such terms refer to a reduction in the levels of IgM serum paraprotein, anemia, hyper-viscosity, neuropathy, coagulopathies, splenomegaly, hepatomegaly, and adenopathy.
- An effective amount of a compound typically will vary from about 0.001 mg/kg to about 1000 mg/kg in one or more dose administrations, for one or several days (depending of course of the mode of administration and the factors discussed above).
- Actual dosage levels of the therapeutic agent can be varied to obtain an amount that is effective to achieve the desired therapeutic response for a particular patient, compositions, and mode of administration.
- the selected dosage level depends upon the activity of the particular compound, the route of administration, the tissue being treated, and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effort and to gradually increase the dosage until the desired effect is achieved.
- compositions can be administered orally, including sublingually, rectally, parenterally, intracisternally, intravaginally,
- compositions of the present invention may include or be diluted into a pharmaceutically- acceptable carrier.
- “pharmaceutically- acceptable carrier” as used herein means one or more compatible fillers, diluants or other such substances, which are suitable for administration to a human or other mammal such as a dog, cat, or horse.
- carrier denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application.
- the carriers are capable of being commingled with the preparations of the present invention, and with each other, in a manner such that there is no interaction which would substantially impair the desired pharmaceutical efficacy or stability.
- Carriers suitable for oral, subcutaneous, intravenous, intramuscular, etc. formulations can be found in Remington's Pharmaceutical Sciences, Mack
- PB Peripheral blood
- WM Peripheral blood
- WM and IgM MGUS patients met consensus criteria for diagnosis, and symptomatic patients met consensus criteria for initiation of therapy.1,24
- Sixty-one untreated WM, 66 previously treated WM, 12 IgM MGUS, 3 polyclonal hyper- IgM syndrome and 1 IgG LPL untreated patients had paired PB and BM samples.
- the clinical characteristics for all and paired WM and IgM MGUS patients are provided in Table 1.
- CD19-selected cells from BM aspirates were isolated as previously reported.7,9 CD19-cells from PB samples were isolated using CD 19 Dynabeads Pan B Kit (Life
- the mutant- specific reverse primer was 5'- CCT TGT ACT TGA TGG GGA aCG-3' (SEQ ID NO: 1) and the wild-type- specific reverse primer was 5'-GCC TTG TAC TTG ATG GGG AaC A-3' (SEQ ID NO: 2).
- the common forward primer was 5'-AAT GTG TGC CAG GGG TAC TTA G-3' (SEQ ID NO: 3).
- PCR reaction was performed in a final volume of 25 ul with 50 nM of each primer and 50 ng DNA using PCR SuperMix High Fidelity (Life technology, CA). Thermal cycling conditions were: 2 min at 94°C, followed by 40 cycles of 94°C for 30s, 57°C for 30s, and 68°C for 30s, with a final extension at 68°C for 5 min.
- the amplified PCR products (159-bp) were separated on 2% agarose gel. To confirm the sequence, PCR products were purified by QIA quick gel extraction kit (Qiagen, CA) and sequenced using both forward and reverse PCR primers.
- Quantitative detection of the MYD88 L265P mutation was developed using the primers described above and Power SYBR® Green PCR Master Mix according to manufacturer's instruction on the ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster City, CA). Briefly, PCR reaction was performed in a final volume of 25 ⁇ with 25 nM of each primer and 50 ng DNA. Thermal cycling conditions were: 10 min at 95°C, followed by 40 cycles of 95°C for 15s and 60°C for 60s. Each sample was assayed in triplicate. The standard curve for MYD88 L265P was generated by a serial dilution of the mutant DNA with the wild-type DNA (50%, 10%, 2%, 0.4%, 0.08%, and wild- type).
- the forward primer is same as the one used for the AS-PCR (5' -AAT GTG TGC CAG GGG TAC TTA G-3' ; (SEQ ID NO: 3)) and the reverse primer is located at 53-bp downstream of the AS-PCR primer (5' -TGG TGT AGT CGC AGA CAG TGA-3' ; (SEQ ID NO: 4)).
- Levels of the mutant MYD88 L265P in patient samples were calculated based on the value of delta CT and the standard curve.
- MYD88 L265P in unselected PB cells from WM patients The feasibility of using real-time AS-PCR assay to detect MYD88-L265P in peripheral blood (PB) using unselected PB mononuclear cells from 88 untreated WM patients was first determined. Eighty-one (92%) of these patients expressed the MYD88- L265P mutation in CD19-selected B-cells derived from BM aspirations. Of the 81 patients who expressed MYD88-L265P, 32 (40%) were positive for MYD88-L265P using unselected PB mononuclear cells.
- CD 19- selected cells from WM patients were isolated with a convenient magnetic based (Dynabead) selection kit.
- the purity of CD 19+ cells isolated with Dynabeads was >80%, and was on par with the yield and purity achieved with Microbeads.
- By quantitative MYD88 L265P AS-PCR assay Dynabead CD19-selected PB cells from 118 untreated WM, 102 previously treated WM, 12 IgM MGUS, 3 hyper-IGM, and 1 IgG LPL patients were then analyzed.
- the median PB MYD88 L265P ACt was 3.77, 7.24, 2.47, 10.89, 12.33, and 14.07 in patients with untreated WM, previously treated WM, IgG LPL, IgM MGUS, hyper- IgM syndrome, and healthy donors, respectively (p ⁇ 0.0001 by ANOVA).
- MYD88 L265P ACt Using a MYD88 L265P ACt of 9.6, 114/118 (96.6%) untreated WM patients, including 49/51 (96.1%) smoldering and 65/67 (97.0%) symptomatic patients were positive (Fig. 1).
- the median PB MYD88 L265P ACt was 3.58 for all untreated WM patients that were positive for PB MYD88 L265P, and 4.51 and 3.18 for those untreated WM patients with smoldering and symptomatic disease, respectively.
- MYD88 L265P was detected in CD19-selected PB cells from previously treated WM patients, though a lower fraction of patients, i.e. 63/102 (61.8%) demonstrated positivity (p ⁇ 0.0001 versus untreated WM patients).
- the median PB MYD88 L265P ACt for positive patients with previously treated disease was 5.05. MYD88 L265P was also detected in a lower fraction of IgM
- MGUS patients i.e. 5/12 (41.2%; p ⁇ 0.0001 versus untreated), as well as in one untreated IgG LPL patient.
- the median PB MYD88 L265P ACt for positive patients with IgM MGUS was 8.22. All 3 hyper- IgM syndrome patients, and 40 healthy donors were negative for MYD88 L265P by AS-PCR examination of PB CD19-selected cells.
- paired analysis of CD19-selected samples from the PB and BM in 61 untreated and 66 previously treated WM patients, and 12 IgM MGUS patients was performed (Fig. 2A).
- the baseline clinical parameters for paired patients did not significantly differ when compared to corresponding patients cohorts that included both paired and unpaired patients (Table 1). Additionally, no significant differences in median prior therapies, time from last therapy, on versus off active therapy and prior treatment with a rituximab containing regimen were observed for paired versus all previously treated patients (data not shown).
- Analysis of paired BM and PB samples from the untreated WM cohort included 13 smoldering and 48 symptomatic patients.
- MYD88 L265P was detected in 12 (92.3%) and 46 (95.7%) CD19- selected BM samples from smoldering and symptomatic untreated WM patients, respectively.
- MYD88 L265P was detected in paired PB CD19-selected samples in 11/12 (92%) and 46/46 (100%) of smoldering and
- MYD88 L265P was detected in 57/58 (98.3%) of the untreated WM patients by PB AS-PCR examination.
- PB results expression for MYD88 L265P in the corresponding BM sample was weakly positive with a ACt close to the cutoff for positivity.
- the 57 untreated WM patients who were positive for MYD88 L265P by PB examination were also positive by BM examination.
- MYD88 L265P was present in 6 (50%) and 5 (41.7%) of the BM and PB CD19-selected samples, respectively. All 5 IgM MGUS patients who were positive for MYD88 L265P by PB examination also expressed this mutation by BM examination; therefore MYD88 L265P was detected in 5/6 (83.3%) of these individuals by PB AS-PCR examination. For the 1 IgM MGUS patient with negative MYD88 L265P PB result but who was positive in the BM, expression for the mutation in the corresponding BM sample was weakly positive with a ACt close to the cutoff for positivity.
- the findings yield a sensitivity of 83.3%, specificity of 100%, positive and negative predictive values of 100% and 85.7%, respectively, for determination of MYD88 L265P by AS-PCR assay using Dynabead CD19-selected PB cells in IgM MGUS patients.
- fewer IgM MGUS patients were MYD88 L265P positive by either BM or PB examination
- BM MYD88 L265P ACt and disease burden correlates with PB MYD88 L265P ACt in untreated and previously treated WM patients.
- MYD88 L265P ACt was compared to BM disease involvement, established by histopathological review, as well as serum IgM and hemoglobin levels in patients who were MYD88 L265P positive by BM examination.
- MYD88 L265P ACt also inversely correlated with BM disease involvement when untreated WM and IgM MGUS patients were combined.
- MYD88 L265P ACt positively also correlated with hemoglobin levels, whereas no significant correlation was observed with either BM or PB MYD88 L265P ACt with absolute lymphocyte count or serum IgM levels in previously treated patients.
- Serum IgM is typically used to monitor MGUS and WM patients for changes in underlying BM disease burden. Therefore, the relative correlations of serum IgM levels and PB MYD88 L265P ACt to underlying BM disease burden in untreated and previously treated WM patients were compared, and a Fisher' s r to z transformation was calculated to assess the significance of the difference between correlations.
- PB MYD88 L265P ACt can distinguish WM from IgM MGUS patients
- the median PB MYD88 L265P ACt for positive IgM MGUS, smoldering WM, and symptomatic untreated WM patients was 8.22, 4.83, and 2.91, respectively (p ⁇ 0.0001 by ANOVA).
- the PB MYD88 L265P ACt cutoff of 6.5 was then applied to the entire untreated WM and IgM MGUS cohort whose positive MYD88 L265P status was determined by PB examination.
- This cohort included 119 untreated patients, inclusive of 49 smoldering and 65 symptomatic WM patients, and 5 patients with IgM MGUS.
- MGUS, smoldering WM, and symptomatic untreated WM patients was 7.96, 4.46, and 3.08, respectively (p ⁇ 0.0001 by ANOVA).
- none of the 5 patients with IgM MGUS had a PB MYD88 L265P ACt of 6.5 or lower (p ⁇ 0.0001).
- a highly sensitive and specific AS-PCR assay was used for determining MYD88 L265P status in BM CD 19- selected cells. Initially, unselected PB cells from untreated WM patients were examined. The low sensitivity (39.5%) for detecting MYD88 L265P by this method prompted examination of the use of CD19-selected PB cells by Dynabead isolation for AS-PCR testing. Dynabeads represent a convenient and affordable means for CD 19 selection, which may easily be adoptable for use in clinical pathology laboratories where flow based sorting is time and cost prohibitive. By use of Dynabead isolation, it was demonstrated that PB MYD88 L265P testing was associated with high rates of sensitivity (98.1%) and specificity (100%) in untreated WM patients.
- MYD88 L265P detection in previously treated patients was associated with a lower sensitivity of 73.7%, and a negative predictive value of 23.8%.
- the specificity (100%) and positive predictive value (100%) in previously treated patients remained high, and coincided with values observed in untreated patients.
- peripheral blood AS-PCR testing for MYD88 L265P may in the appropriate clinical context be used to establish the diagnosis of WM.
- Appropriate clinical context could include demonstration of cytopenias in the absence of other medical etiologies, and/or presence of morbidities attributable to WM such as hyperviscosity, adenopathy or splenomegaly in the presence of elevated serum IgM levels and the presence of an IgM monoclonal protein.
- Use of PB MYD88 L265P ACt as demonstrated herein, could also help distinguish WM from IgM MGUS patients who are typically asymptomatic, have low serum IgM levels, and lack cytopenias and/or extramedullary disease.
- a BM biopsy may then be considered in order to clarify the underlying diagnosis.
- Similar molecular based testing has obviated the need for routine bone marrow examination in patients with other hematological conditions including chronic myelogenous leukemia (BCR-ABL), polycythemia vera (JAK2 V617F) and hairy cell leukemia (BRAF V600E).25-27
- BCR-ABL chronic myelogenous leukemia
- JAK2 V617F polycythemia vera
- BRAF V600E hairy cell leukemia
- PB MYD88 L265P testing including serial assessment of MYD88 L265P ACt values in patients undergoing therapy could be useful in assessing not only treatment response, but also the differential impact of treatment on PB and BM compartments.
- BM MYD88 L265P ACt to assess changes in BM tumor burden following therapy has previously been demonstrated, and the high degree of correlation between PB and BM MYD88 L265P ACt as shown in these studies supports the investigation of PB MYD88 L265P ACt in prospective therapeutic trials.
- PB MYD88 L265P ACt to estimate underlying disease burden in patients undergoing treatments which differentially affect serum IgM levels can help guide clinical management, and avoid repetition of BM biopsies to clarify IgM discordance as is the current standard of care.
- Treon SP Hunter ZR, Matous J, et al. Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03- 248. Clin Cancer Res 2007; 13:3320-5.
- Treon SP Tripsas CK, Ioakimidis L, et al. Prospective, Multicenter Study of the Mtor Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's
- Table 1 Baseline characteristics of patients with WM and IgM MGUS. Median values provided, p-values denote significance by ANOVA for comparisons within WM and IgM MGUS cohorts for all patients, and for BM and PB paired patients.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14868118.2A EP3077001B1 (en) | 2013-12-06 | 2014-12-04 | Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
AU2014360426A AU2014360426B2 (en) | 2013-12-06 | 2014-12-04 | Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
CA2930326A CA2930326C (en) | 2013-12-06 | 2014-12-04 | Methods to distinguish waldenstrom's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
US15/102,034 US10612095B2 (en) | 2013-12-06 | 2014-12-04 | Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361912842P | 2013-12-06 | 2013-12-06 | |
US61/912,842 | 2013-12-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015085075A1 true WO2015085075A1 (en) | 2015-06-11 |
Family
ID=53274120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/068579 WO2015085075A1 (en) | 2013-12-06 | 2014-12-04 | Methods to distinguish waldenström's macroglobulinemia from igm monoclonal gammopathy of undetermined significance |
Country Status (5)
Country | Link |
---|---|
US (1) | US10612095B2 (en) |
EP (1) | EP3077001B1 (en) |
AU (1) | AU2014360426B2 (en) |
CA (1) | CA2930326C (en) |
WO (1) | WO2015085075A1 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017004599A1 (en) * | 2015-07-01 | 2017-01-05 | Neogenomics Laboratories, Inc. | Method for high sensitivity detection of myd88 mutations |
US10253370B2 (en) | 2015-08-17 | 2019-04-09 | Neogenomics Laboratories, Inc. | High-sensitivity sequencing to detect BTK inhibitor resistance |
US10329605B2 (en) | 2015-04-20 | 2019-06-25 | Neogenomics Laboratories, Inc. | Method to increase sensitivity of detection of low-occurrence mutations |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2624981T3 (en) | 2011-07-01 | 2017-07-18 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in the MYD88 gene in lymphoplasmocytic lymphoma |
AU2014318614B2 (en) | 2013-09-12 | 2021-01-07 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
CN109152781A (en) | 2016-04-29 | 2019-01-04 | 达纳-法伯癌症研究所有限公司 | HCK as the therapeutic targets in MYD88 mutation diseases |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040137489A1 (en) * | 2002-12-05 | 2004-07-15 | Shaughnessy John D. | Molecular determinants of myeloma bone disease and uses thereof |
WO2006006709A1 (en) | 2004-07-12 | 2006-01-19 | Matsushita Electric Industrial Co., Ltd. | Stream recording/reproducing apparatus |
WO2013006443A2 (en) | 2011-07-01 | 2013-01-10 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006067091A1 (en) | 2004-12-20 | 2006-06-29 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Myd88 homodimerization inhibitors |
ES2553553T3 (en) | 2006-10-02 | 2015-12-10 | E. R. Squibb & Sons, L.L.C. | Human antibodies that bind to CXCR4 and their uses |
US20120065201A1 (en) | 2007-03-28 | 2012-03-15 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
US8394816B2 (en) | 2007-12-07 | 2013-03-12 | Irene Ghobrial | Methods of using [3.2.0] heterocyclic compounds and analogs thereof in treating Waldenstrom's Macroglobulinemia |
US7824861B2 (en) * | 2008-07-10 | 2010-11-02 | National Tsing Hua University | Method for quantitative analysis of transcripts with nucleotide polymorphism at specific site |
KR20140020368A (en) | 2008-12-23 | 2014-02-18 | 제넨테크, 인크. | Methods and compositions for diagnostic use in cancer patients |
US20120071497A1 (en) | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
HUE043001T2 (en) | 2011-11-09 | 2019-07-29 | Bristol Myers Squibb Co | Treatment of hematologic malignancies with an anti-cxcr4 antibody |
WO2014017659A1 (en) | 2012-07-27 | 2014-01-30 | 独立行政法人理化学研究所 | Agent for treating or controlling recurrence of acute myelogenous leukemia |
AU2014318614B2 (en) | 2013-09-12 | 2021-01-07 | Dana-Farber Cancer Institute Inc. | Methods for evaluating and treating Waldenstrom's macroglobulinemia |
CN109152781A (en) | 2016-04-29 | 2019-01-04 | 达纳-法伯癌症研究所有限公司 | HCK as the therapeutic targets in MYD88 mutation diseases |
-
2014
- 2014-12-04 WO PCT/US2014/068579 patent/WO2015085075A1/en active Application Filing
- 2014-12-04 CA CA2930326A patent/CA2930326C/en active Active
- 2014-12-04 AU AU2014360426A patent/AU2014360426B2/en active Active
- 2014-12-04 US US15/102,034 patent/US10612095B2/en active Active
- 2014-12-04 EP EP14868118.2A patent/EP3077001B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040137489A1 (en) * | 2002-12-05 | 2004-07-15 | Shaughnessy John D. | Molecular determinants of myeloma bone disease and uses thereof |
WO2006006709A1 (en) | 2004-07-12 | 2006-01-19 | Matsushita Electric Industrial Co., Ltd. | Stream recording/reproducing apparatus |
WO2013006443A2 (en) | 2011-07-01 | 2013-01-10 | Dana-Farber Cancer Institute, Inc. | Discovery of a somatic mutation in myd88 gene in lymphoplasmacytic lymphoma |
WO2013052699A2 (en) | 2011-10-04 | 2013-04-11 | Gilead Calistoga Llc | Novel quinoxaline inhibitors of pi3k |
Non-Patent Citations (38)
Title |
---|
"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues", 2008, IARC PRESS |
ANDERSON KCALSINA MBENSINGER W ET AL.: "Multiple Myeloma, version 1.2013", J NATL COMPR CANC NETW., vol. 11, no. 1, 1 January 2013 (2013-01-01), pages 11 - 7 |
ARGENTOU NVASSILOPOULOS GIOANNOU M ET AL.: "Rapid detection of MYD88-L265P mutation by PCR-RFLP in B-cell lymphoproliferative disorders", LEUKEMIA, 18 October 2013 (2013-10-18) |
BOSSUYT ET AL.: "Serum protein electrophoresis and immunofixation by a semiautomated electrophoresis system", CLINICAL CHEMISTRY, vol. 44, no. 5, May 1998 (1998-05-01), pages 944 - 949 |
GACHARD NPARRENS MSOUBEYRAN I ET AL.: "IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenstrom macroglobulinemia/lymphoplasmacytic lymphomas", LEUKEMIA, vol. 27, 2013, pages 183 - 9 |
HODGE LSZIESMER SCYANG ZZ ET AL.: "IL-21 in the bone marrow microenvironment contributes to IgM secretion and proliferation of malignant cells in Waldenstrom macroglobulinemia", BLOOD, vol. 120, no. 18, 1 November 2012 (2012-11-01), pages 3774 - 82 |
JIMENEZ CSEBASTIAN EDEL CARMEN CHILLON M ET AL.: "MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia", LEUKEMIA, vol. 27, no. 8, August 2013 (2013-08-01), pages 1722 - 8, XP055164174, DOI: doi:10.1038/leu.2013.62 |
KISS TLXU WMJAMAL NMESSNER HA: "Comparative testing of peripheral blood and bone marrow for BCR-ABL transcripts in patients post allogeneic bone marrow transplantation and during interferon treatment for chronic myeloid leukemia", LEUK LYMPHOMA, vol. 34, no. 5-6, August 1999 (1999-08-01), pages 493 - 500 |
KRIANGKUM JTAYLOR BJTREON SP ET AL.: "Clonotypic IgM V/D/J sequence analysis in Waldenstrom macroglobulinemia suggests an unusual B-cell origin and an expansion of polyclonal B cells in peripheral blood", BLOOD, vol. 104, no. 7, 1 October 2004 (2004-10-01), pages 2134 - 42 |
KYLE RATREON SPALEXANIAN R ET AL.: "Prognostic markers and criteria to initiate therapy in Waldenstrom's Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia", SEMIN ONCOL, vol. 30, 2003, pages 116 - 120 |
LANDGREN OSTAUDT L: "MYD88 L265P somatic mutation in IgM MGUS", N ENGL J MED, vol. 367, 2012, pages 2255 - 6 |
LIN SCLO YCWU H: "Helical assembly in the MYD88-IRAK4-IRAK2 complex in TLR/IL-1R signaling", NATURE, vol. 465, no. 7300, 2010, pages 885 - 891, XP055358912, DOI: doi:10.1038/nature09121 |
LOIARRO MGALLO GFANTO NDE SANTIS RCARMINATI PRUGGIERO VSETTE C: "Identification of critical residues of the MYD88 death domain involved in the recruitment of downstream kinases", J BIOL CHEM., vol. 284, no. 41, 2009, pages 28093 - 281023 |
NGO HTLELEU XLEE JJIA XMELHEM MRUNNELS JMOREAU ASBURWICK NAZAB AKROCCARO A: "SDF-1/CXCR4 and VLA-4 interaction regulates homing in Waldenstrom macroglobulinemia", BLOOD, vol. 112, no. 1, 1 July 2008 (2008-07-01), pages 150 - 8 |
NGO VNYOUNG RMSCHMITZ R ET AL.: "Oncogenically active MYD88 mutations in human lymphoma", NATURE, vol. 470, no. 7332, 2011, pages 115 - 9, XP055141842, DOI: doi:10.1038/nature09671 |
O'CONNELL ET AL.: "Understanding and Interpreting Serum Protein Electrophoresis", AM FAM PHYSICIAN, vol. 71, no. 1, 1 January 2005 (2005-01-01), pages 105 - 112 |
ONDREJKA SLLIN JJWARDEN DW ET AL.: "MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders", AM J CLIN PATHOL., vol. 140, no. 3, September 2013 (2013-09-01), pages 387 - 94 |
OWEN RGTREON SPAL-KATIB AFONSECA RGREIPP PRMCMASTER MLMORRA EPANGALIS GASAN MIGUEL JFBRANAGAN AR: "Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia", SEMIN ONCOL., vol. 30, no. 2, 2003, pages 110 - 115 |
PASSAMONTI F.: "How I treat polycythemia vera", BLOOD, vol. 120, no. 2, 12 July 2012 (2012-07-12), pages 275 - 84 |
POULAIN SROUMIER CDECAMBRON A ET AL.: "MYD88 L265P mutation in Waldenstrom's macroglobulinemia", BLOOD, vol. 121, no. 22, 30 May 2013 (2013-05-30), pages 4504 - 11 |
PUENTE XSPINYOL MQUESADA V ET AL.: "Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia", NATURE, vol. 475, no. 7354, 2011, pages 101 - 105, XP055164265, DOI: doi:10.1038/nature10113 |
See also references of EP3077001A4 |
SMITH BRROBERT NJAULT KA: "In Waldenstrom's macroglobulinemia the quantity of detectable circulating monoclonal B lymphocytes correlates with clinical course", BLOOD, vol. 61, no. 5, May 1983 (1983-05-01), pages 911 - 4 |
TIACCI ESCHIAVONI GFORCONI F ET AL.: "Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation", BLOOD, vol. 119, 2012, pages 192 - 195, XP055054550, DOI: doi:10.1182/blood-2011-08-371179 |
TREON ET AL.: "A new era for Waldenstrom macroglobulinemia: MYD88 L265P", BLOOD, vol. 121, 30 May 2013 (2013-05-30), pages 4434 - 4436, XP055348363 * |
TREON ET AL.: "MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia", N ENGL J MED, vol. 367, 30 August 2012 (2012-08-30), pages 826 - 833, XP055141863 * |
TREON SP: "How I treat Waldenstrom macroglobulinemia", BLOOD, vol. 114, no. 12, 2009, pages 2375 - 85 |
TREON SPHUNTER ZR: "MYD88 L265P Somatic Mutation in IgM MGUS", NEW ENGLAND JOURNAL OF MEDICINE, vol. 367, 2012, pages 2256 - 2257 |
TREON SPHUNTER ZRMATOUS J ET AL.: "Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248", CLIN CANCER RES, vol. 13, 2007, pages 3320 - 5 |
TREON SPTRIPSAS CKIOAKIMIDIS L ET AL.: "Prospective, Multicenter Study of the Mtor Inhibitor Everolimus (RAD001) As Primary Therapy in Waldenstrom's Macroglobulinemia", BLOOD, vol. 118, 2011, pages 2951 |
TREON SPTRIPSAS CYANG G ET AL.: "A Prospective Multicenter Study Of The Bruton's Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom's Macroglobulinemia", PROC. OF THE AMERICAN SOCIETY OF HEMATOLOGY. BLOOD, 2013 |
TREON SPXU LYANG G ET AL.: "MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia", N ENGL J MED, vol. 367, 2012, pages 826 - 33, XP055141863, DOI: doi:10.1056/NEJMoa1200710 |
VARETTONI MARCAINI LZIBELLINI S ET AL.: "Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms", BLOOD, vol. 121, 2013, pages 2522 - 8, XP055372773, DOI: doi:10.1182/blood-2012-09-457101 |
WATTERS TKENNY EFO'NEILL LAJ: "Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins", IMMUNOL CELL BIOL., vol. 85, no. 6, 2007, pages 411 - 419 |
WILLENBACHER WWILLENBACHER EBRUNNER A ET AL.: "Improved accuracy of discrimination between IgM Multiple Myeloma and Waldenstrom Macroglobulinaemia by testing for MYD88 L265P mutations", BR J HAEMATOL 2013; BR J HAEMATOL., vol. 161, no. 6, June 2013 (2013-06-01), pages 902 - 4 |
XU ET AL., BLOOD, vol. 121, no. 11, 14 March 2013 (2013-03-14), pages 2051 - 8 |
XU LHUNTER ZRYANG G ET AL.: "MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction", BLOOD, vol. 121, 2013, pages 2051 - 8, XP055372626, DOI: doi:10.1182/blood-2012-09-454355 |
YANG GZHOU YLIU X ET AL.: "A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia", BLOOD, vol. 122, no. 7, 2013, pages 1222 - 32, XP055281747, DOI: doi:10.1182/blood-2012-12-475111 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10329605B2 (en) | 2015-04-20 | 2019-06-25 | Neogenomics Laboratories, Inc. | Method to increase sensitivity of detection of low-occurrence mutations |
WO2017004599A1 (en) * | 2015-07-01 | 2017-01-05 | Neogenomics Laboratories, Inc. | Method for high sensitivity detection of myd88 mutations |
US10227657B2 (en) | 2015-07-01 | 2019-03-12 | Neogenomics Laboratories, Inc. | Method for high sensitivity detection of MYD88 mutations |
US10253370B2 (en) | 2015-08-17 | 2019-04-09 | Neogenomics Laboratories, Inc. | High-sensitivity sequencing to detect BTK inhibitor resistance |
Also Published As
Publication number | Publication date |
---|---|
EP3077001A1 (en) | 2016-10-12 |
CA2930326A1 (en) | 2015-06-11 |
CA2930326C (en) | 2022-09-06 |
EP3077001A4 (en) | 2017-06-28 |
US20160304958A1 (en) | 2016-10-20 |
AU2014360426A1 (en) | 2016-06-02 |
EP3077001B1 (en) | 2020-04-15 |
AU2014360426B2 (en) | 2020-05-07 |
US10612095B2 (en) | 2020-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014360426B2 (en) | Methods to distinguish Waldenstrom's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance | |
US11739385B2 (en) | Discovery of a somatic mutation in MYD88 gene in lymphoplasmacytic lymphoma | |
JP7323393B2 (en) | Methods of treating cancer patients with farnesyltransferase inhibitors | |
Wei et al. | Germline lysine-specific demethylase 1 (LSD1/KDM1A) mutations confer susceptibility to multiple myeloma | |
Silver et al. | The effect of initial molecular profile on response to recombinant interferon‐α (rIFNα) treatment in early myelofibrosis | |
Gerds et al. | Myeloproliferative neoplasms, version 3.2022, NCCN clinical practice guidelines in oncology | |
Wrensch et al. | The molecular epidemiology of gliomas in adults | |
Courtois et al. | IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition | |
Hsiao et al. | The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia | |
Pan et al. | Molecular analysis of HLA-DRB1 allelic associations with systemic lupus erythematous and lupus nephritis in Taiwan | |
JP2018148863A (en) | Genetic risk detection for kidney related disease | |
Hazenberg et al. | Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study | |
Mimiola et al. | Systemic mastocytosis associated with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis: Report of three cases | |
JP2023524048A (en) | Composite biomarkers for cancer immunotherapy | |
Minns et al. | DIPG-45. Radiation induces a robust interferon response in Diffuse Midline Glioma (DMG), improving the potential for combination immunotherapy | |
US20070289889A1 (en) | Biomarkers For The Prediction Of Drug-In Duced Diarrhea | |
US20230167166A1 (en) | Targeted therapy for the treatment & prevention of life-threatening complications of infection | |
Dye | Identifying Epigenetic Signatures in Monocytes of HIV-Associated Co-Morbidities | |
KR20210097160A (en) | Methods of Treatment of Follicular Lymphoma | |
US20140135288A1 (en) | Selecting use of proteasome inhibitors based on nf-kb2 sequence | |
Park et al. | SUN-199 URINARY ANGIOTENSINOGEN TO CREATININE RATIO (UAGT/CR) IS NOT A PREDICTIVE BIOMARKER FOR RENAL PROGRESSION IN AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: KNOW-CKD STUDY | |
CA3129593A1 (en) | Combination therapy for treatment of b-cell malignancies | |
JP6074841B2 (en) | Inspection method using leukocyte antigen marker | |
Cacciola et al. | Effect of anagrelide on JAK2 mutational status in patients with essential thrombocythemia | |
Chena et al. | Association of toll-like receptor 4 gene polymorphisms with primary membranous nephropathy in a high prevalence renal disease area in Taiwan |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14868118 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2930326 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2014360426 Country of ref document: AU Date of ref document: 20141204 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15102034 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2014868118 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014868118 Country of ref document: EP |